GSK Secures Rights to Hansoh’s ADC Candidate in Deal Exceeding $1.7 Billion

GSK’s Multi-Billion-Dollar Deal for Cancer Breakthrough: Unlocking Potent ADC Therapy.

In a groundbreaking move, GSK has secured exclusive rights to HS-20093, a cutting-edge B7-H3-targeted ADC developed by Hansoh Pharma, set to revolutionize cancer treatment. The deal, valued at over $1.7 billion, marks a significant leap in oncology innovation.

This novel ADC, HS-20093, is a game-changer in the fight against solid tumors, spanning lung cancer, sarcoma, and head and neck cancers. It has already showcased promising clinical activity in various cancers, demonstrating its potential through the ARTEMIS-001 trial presented at the American Society of Clinical Oncology annual meeting.

Hesham Abdullah, GSK’s Senior Vice President of Global Head Oncology, Research and Development, highlighted the critical importance of B7-H3 in targeting a wide range of solid tumors where effective treatments are urgently needed.

Under this groundbreaking agreement, GSK secures exclusive global rights, excluding specific regions, to drive the clinical development and commercialization of HS-20093. The deal involves an upfront payment of $185 million to Hansoh, alongside potential success-based milestones amounting to $1.525 billion, along with tiered royalties.

Abdullah emphasized GSK’s commitment to advancing HS-20093 across multiple indications and exploring potential combination approaches within their existing portfolio.

Eliza Sun, Executive Director of Hansoh’s board, expressed enthusiasm for the partnership, citing HS-20093’s encouraging clinical progress in lung cancer and the pivotal role it could play in transforming cancer treatment on a global scale.

This landmark agreement follows closely on the heels of another significant collaboration between GSK and Hansoh. Just two months prior, they inked a deal for HS-20089, targeting the B7-H4 surface antigen prevalent in ovarian and endometrial cancers, representing a $1.57 billion potential agreement.

Abdullah previously highlighted the potential of HS-20089 in treating gynecologic cancers, affirming GSK’s dedication to pioneering novel therapies for patients facing these challenging diseases.